JP2014514248A5 - - Google Patents

Download PDF

Info

Publication number
JP2014514248A5
JP2014514248A5 JP2013554477A JP2013554477A JP2014514248A5 JP 2014514248 A5 JP2014514248 A5 JP 2014514248A5 JP 2013554477 A JP2013554477 A JP 2013554477A JP 2013554477 A JP2013554477 A JP 2013554477A JP 2014514248 A5 JP2014514248 A5 JP 2014514248A5
Authority
JP
Japan
Prior art keywords
damage
animal
ufa
vitamin
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013554477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024137 external-priority patent/WO2012112340A2/en
Publication of JP2014514248A publication Critical patent/JP2014514248A/ja
Publication of JP2014514248A5 publication Critical patent/JP2014514248A5/ja
Pending legal-status Critical Current

Links

JP2013554477A 2011-02-18 2012-02-07 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物 Pending JP2014514248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161463594P 2011-02-18 2011-02-18
US61/463,594 2011-02-18
PCT/US2012/024137 WO2012112340A2 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Publications (2)

Publication Number Publication Date
JP2014514248A JP2014514248A (ja) 2014-06-19
JP2014514248A5 true JP2014514248A5 (enExample) 2015-03-26

Family

ID=46673093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013554477A Pending JP2014514248A (ja) 2011-02-18 2012-02-07 動物の神経系への損傷を治療、軽減、又は予防するための方法及び組成物

Country Status (11)

Country Link
US (1) US20130324608A1 (enExample)
EP (1) EP2675447A4 (enExample)
JP (1) JP2014514248A (enExample)
CN (1) CN103764136A (enExample)
AU (1) AU2012218094A1 (enExample)
BR (1) BR112013020802A2 (enExample)
CA (1) CA2827715A1 (enExample)
MX (1) MX2013009544A (enExample)
RU (1) RU2013142437A (enExample)
WO (1) WO2012112340A2 (enExample)
ZA (1) ZA201306990B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108808A2 (en) * 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US20160331712A1 (en) * 2013-12-19 2016-11-17 Tassos Georgiou Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
CN104146253A (zh) * 2014-08-13 2014-11-19 胡安然 癫痫全营养配方食品
CN110913689A (zh) * 2017-05-10 2020-03-24 罗切斯特大学 治疗神经精神病症的方法
CN109300527A (zh) * 2018-12-14 2019-02-01 苏州大学 饮食信息的推荐方法
WO2021247124A1 (en) * 2020-06-01 2021-12-09 Corona Feed Additives, L.L.C. Composition, system and method for a pig contraceptive
US20230016955A1 (en) * 2020-06-01 2023-01-19 Corona Feed Additives, L.L.C. Animal Contraceptive
MX2022015535A (es) * 2020-06-16 2023-01-30 Md Healthcare Inc Composicion para la prevencion o el tratamiento de trastornos neurologicos o mentales que comprenden vesiculas extraceluares derivadas de lactobacillus paracasei.
CN113368171A (zh) * 2021-06-18 2021-09-10 长江大学 枸杞在预防放射治疗导致的认知功能障碍药物中的应用
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883087A (en) * 1991-01-07 1999-03-16 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
NZ516513A (en) * 1999-06-14 2004-03-26 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2002336638A1 (en) * 2001-10-12 2003-04-28 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
US20040186488A1 (en) * 2003-03-17 2004-09-23 Droese Karl William Method of peripheral nerve reconstruction using a micro suction connector
US6951658B1 (en) * 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
CA2598525A1 (en) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. Nerve regeneration promoting agent
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
JP2008533005A (ja) * 2005-03-11 2008-08-21 ヴァーダ コンサルティング リミテッド 生物学的活性物質の皮内的、経皮的又は経粘膜的送達のための方法
EP1915613A4 (en) * 2005-07-08 2008-11-05 Philadelphia Health & Educatio METHOD FOR MONITORING THE NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR THE TREATMENT OF DISEASES COMPRISING A COMPOSITION COMPONENT RELATED TO PHOSPHOLIPASE A2
ES2365628T3 (es) * 2005-08-26 2011-10-07 Nestec S.A. Composiciones y métodos para mejorar la integridad vascular funcional, la supervivencia celular y la reducción de la apoptosis después de un episodio isquémico en el cerebro.
WO2007022991A1 (en) 2005-08-26 2007-03-01 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
CN101909632A (zh) * 2008-01-04 2010-12-08 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders

Similar Documents

Publication Publication Date Title
JP2014514248A5 (enExample)
JP5979816B2 (ja) 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用
JP5931337B2 (ja) 認知機能を高める組成物及び方法
RU2597793C2 (ru) Способы и композиции для лечения, ослабления или предотвращения ухудшения зрительной системы животных
JP2010540636A5 (enExample)
EP2675447A2 (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
RS51195B (sr) Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
CN113813252B (zh) 一种ω-3多不饱和脂肪酸组合物及其制备方法
EP3461479B1 (en) Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
CA2838976C (en) Dha and epa in the reduction of oxidative stress
JP2023030130A (ja) 認知症ではない個体において認知的加齢を軽減する組成物の製造方法
US11284633B2 (en) Pet food composition for managing non-food allergies
CN105341919B (zh) 一种改善记忆力的药物组合物及其制备方法
CN106232114A (zh) 周围神经病变的预防或改善用组合物
US20210329945A1 (en) Infused Antler Animal Chew and Methods of Manufacture and Packaging
Kwochka Fatty acids in veterinary dermatology and beyond: mechanism of action, clinical indications and quality
Hielm-Bjorkman Novel pain management options: nutraceuticals
US20180085382A1 (en) Compositions and methods for cognitive health and memory
Gunn-Moore Feline cognitive dysfunction syndrome.